Table 2.
Selected anti-VEGF kinase inhibitor agents currently under evaluation in mCRCa
| Agent | Combination | ClinicalTrials.gov (NCT#) | Phase | Trial completed? |
|---|---|---|---|---|
| Axitinib | Axitinib + FOLFOX | NCT0061505660 | 2 | Yes |
| Axitinib + FOLFIRI | ||||
| Single agent | NCT0149086661 | 2 | No | |
| BIBF1120 | BIBF1120 + mFOLFOX6 | NCT0090483962 | 2 | Yes |
| Bevacizumab + mFOLFOX6 | ||||
| Brivanib | Brivanib + Cetuximab | NCT0064047163 | 3 | Yes |
| Brivanib + Placebo | ||||
| Cediranib | Cediranib + FOLFOX | NCT0038417664 (HORIZON III) | 3 | No |
| Bevacizumab + FOLFOX | ||||
| Sunitinib | Sunitinib + FOLFIRI | NCT0045769165 | 3 | Yes |
| Placebo + FOLFIRI | ||||
| Sorafenib | Sorafenib + FOLFOX or FOLFIRI | NCT0088934366 | 2 | Terminated |
| Placebo + FOLFOX or FOLFIRI | ||||
| Regorafenib | Regorafenib | NCT0110332367 | 3 | No |
| Placebo | 3 | No | ||
| Regorafenib | NCT01538680 (CONSIGN)68 | |||
| Vandetanib | Vandetanib + FOLFOX | NCT0050029269 | 2 | No |
| Placebo + FOLFOX | 2 | Yes | ||
| Vandetanib + FOLFIRI | NCT0045411670 | |||
| Placebo + FOLFIRI |
Note:
a
List is not meant to be exhaustive.
Abbreviations: mCRC, metastatic colorectal cancer; NCT, National Clinical Trial; VEGF, vascular endothelial growth factor.